Guangzhou Wondfo Biotech Co.,Ltd (SHE:300482)
China · Delayed Price · Currency is CNY 17.41
-0.23 (-1.30%)
Aug 4, 2026, 3:04 PM CST
SHE:300482 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,868 | 2,087 | 3,065 | 2,765 | 5,681 | 3,361 |
Revenue Growth | -37.81% | -31.91% | 10.85% | -51.33% | 69.01% | 19.57% |
Gross Profit Gross Profit Growth | 1,012 | 1,178 | 1,957 | 1,725 | 2,933 | 1,965 |
Operating Income Operating Income Growth | -234.6 | -126.97 | 590.27 | 456.73 | 1,324 | 634.64 |
Net Income Net Income Growth | -167.76 | -63.02 | 561.63 | 487.62 | 1,197 | 634.43 |
Earnings Per Share EPS Growth | -0.35 | -0.13 | 1.21 | 1.10 | 2.71 | 1.43 |
EPS Growth | - | - | 10.00% | -59.41% | 89.51% | -0.69% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
In Vitro Diagnostic Product In Vitro Diagnostic Product Growth | 2,023 | 2,991 | 2,668 |
Others Others Growth | 64.08 | 73.96 | 97.12 |
Total Total Growth | 2,087 | 3,065 | 2,765 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,971 | 2,101 | 2,198 | 2,186 | 2,301 | 1,569 |
Total Debt Total Debt Growth | 607.48 | 601.65 | 605.57 | 603.8 | 768.96 | 581.01 |
Net Cash (Debt) Net Cash Growth | 1,364 | 1,500 | 1,592 | 1,582 | 1,532 | 987.87 |
Net Cash Growth | 1.89% | -5.81% | 0.65% | 3.27% | 55.07% | 9.88% |
Net Cash Per Share Net Cash Per Share Growth | 2.84 | 3.09 | 3.43 | 3.57 | 3.47 | 2.23 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 830 | 463.04 | 361.71 | 328.68 | 1,682 | 664.93 |
Capital Expenditures CapEx Growth | -276.84 | -304.55 | -318.21 | -432.73 | -583.19 | -456.49 |
Free Cash Flow Free Cash Flow Growth | 553.16 | 158.49 | 43.5 | -104.05 | 1,099 | 208.44 |
Free Cash Flow Growth | - | 264.35% | - | - | 427.24% | -67.55% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 54.17% | 56.43% | 63.87% | 62.37% | 51.64% | 58.46% |
Operating Margin | -12.56% | -6.08% | 19.26% | 16.52% | 23.31% | 18.88% |
Pretax Margin | -12.45% | -5.50% | 20.54% | 19.56% | 24.02% | 20.25% |
Profit Margin | -8.98% | -3.02% | 18.32% | 17.64% | 21.07% | 18.88% |
FCF Margin | 29.61% | 7.60% | 1.42% | -3.76% | 19.35% | 6.20% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.220 | 0.220 | 0.400 | 0.400 | 0.500 | 0.300 |
Dividend Per Share Growth | -45.00% | -45.00% | 0% | -20.00% | 66.67% | -22.00% |
Dividend Yield | 1.26% | 1.13% | 1.84% | 1.39% | 1.67% | 0.82% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 19.07 | 27.35 | 11.77 | 27.62 |
Forward PE | 20.05 | 18.44 | 14.64 | 21.86 | 12.49 | 19.74 |
P/FCF Ratio | 14.81 | 57.89 | 246.19 | - | 12.82 | 84.06 |
PS Ratio | 4.39 | 4.40 | 3.49 | 4.82 | 2.48 | 5.21 |